Data fraud allegedly delayed FDA nod for Pfizer-BMS drug Eliquis

Data errors and alleged fraud at clinical trial sites in China held up approval of Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) clot-fighting drug Eliquis, according to media reports. The allegations could raise more questions about the integrity of drug research in China. Report